Table 2.
Patient demographics and baseline characteristics
| Characteristic | Lipid-lowering drug treatment | No lipid-lowering drug treatment | P value | |||
|---|---|---|---|---|---|---|
| Total (n = 1940) | With CVD (n = 1885) | Total (n = 2828) | With CVD (n = 1787) | Without CVD (n = 1041) | Treated vs non-treated (total populations) | |
| Male, % | 58 | 58 | 50 | 48* | 53 | <0.001 |
| Age, years | 57.9 (9.0) | 57.9 (9.0) | 55.7 (10.1) | 57.1* (9.7) | 53.1 (10.4) | <0.001 |
| Weight, kg | 89.4 (19.1) | 89.6 (19.1) | 86.5 (21.2) | 88.5* (20.3) | 83.3 (22.2) | <0.001 |
| BMI, kg/m2 | 31.4 (5.4) | 31.5 (5.4) | 30.9 (6.1) | 31.7* (5.8) | 29.6 (6.5) | 0.004 |
| T2D duration, years | 9.1 (6.3) | 9.1 (6.3) | 8.5 (5.8) | 8.7* (5.9) | 8.0 (5.5) | <0.001 |
| HbA1c, % | 8.75 (1.03) | 8.75 (1.03) | 8.89 (1.08) | 8.84* (1.06) | 8.98 (1.11) | <0.001 |
| FPG, mg/dL | 196 (56) | 196 (55) | 200 (57) | 200 (57) | 201 (58) | 0.01 |
| FPG, mmol/L | 10.9 (3.1) | 10.9 (3.1) | 11.1 (3.2) | 11.1 (3.2) | 11.2 (3.2) | 0.01 |
| Fasting C-peptide, nmol/L | 1.18 (0.59) | 1.19 (0.60) | 1.10 (0.60) | 1.15 (0.59) | 1.01 (0.60) | <0.001 |
Data presented represent mean (standard deviation) unless otherwise specified
HbA1c glycosylated haemoglobin, BMI body mass index, CVD cardiovascular disease, T2D type 2 diabetes, FPG fasting plasma glucose
* Statistically significant differences (P < 0.01) between with-CVD and without-CVD groups